专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2229589B1 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 有权
标题翻译：作为制作具体的治疗学的生物标志物量身打造的面板个性化的治疗KRANKEITSSTOFFWECHSELWEGEN化进程
公开(公告)号：EP2229589B1
公开(公告)日：2015-06-10
申请号：EP08860005.1
申请日：2008-12-10
申请人： Blume-Jensen, Peter
发明人： Blume-Jensen, Peter
IPC分类号： G01N33/48 , G01N33/53
CPC分类号： C12Q1/6883

2. 发明公开

EP2229589A4 DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS 有权
标题翻译：程序对KRANKHEITSWEGBASIS于产生特定的治疗学量身定做生物标志物组
公开(公告)号：EP2229589A4
公开(公告)日：2012-01-04
申请号：EP08860005
申请日：2008-12-10
申请人： BLUME-JENSEN PETER
发明人： BLUME-JENSEN PETER
IPC分类号： G01N33/48 , G01N33/53
CPC分类号： C12Q1/6883

3. 发明公开

EP2229589A1 DISEASE PATHWAY-BASED METHOD TO GENEFJATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS 有权
标题翻译：作为制作具体的治疗学的生物标志物量身打造的面板个性化的治疗KRANKEITSSTOFFWECHSELWEGEN化进程
公开(公告)号：EP2229589A1
公开(公告)日：2010-09-22
申请号：EP08860005.1
申请日：2008-12-10
申请人： Blume-Jensen, Peter
发明人： Blume-Jensen, Peter
IPC分类号： G01N33/48 , G01N33/53
CPC分类号： C12Q1/6883
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.

4. 发明专利

IL178736D0 RNAi-BASED TARGET IDENTIFICATION AND VALIDATION 未知
公开(公告)号：IL178736D0
公开(公告)日：2007-02-11
申请号：IL17873606
申请日：2006-10-19
申请人： BLUME JENSEN PETER , SERONO LAB , APPLIED RESEARCH SYSTEMS
IPC分类号： C12N15/10 , C12Q1/68

5. 发明专利

DK2229589T3 Sygdomsforløbsbaseret fremgangsmåde til at generere biomarkørgrupper, der er tilpasset til særlige terapier til individualiserede behandlinger 未知
公开(公告)号：DK2229589T3
公开(公告)日：2015-08-10
申请号：DK08860005
申请日：2008-12-10
申请人： BLUME-JENSEN PETER
发明人： BLUME-JENSEN PETER
IPC分类号： G01N33/48 , G01N33/53

6. 发明专利

IL175932D0 METHODS FOR IDENTIFYING MODULATORS OF ACTIVE KIT TYROSINE KINASE RECEPTORS 未知
公开(公告)号：IL175932D0
公开(公告)日：2006-10-05
申请号：IL17593206
申请日：2006-05-25
申请人： ARKINSTALL STEPHEN J , BLUME JENSEN PETER , ANDREEV JULIAN , HAEALEY BRIAN , DONG RONG , SERONO LAB , APPLIED RESEARCH SYSTEMS
IPC分类号： G01N33/50 , G01N33/574 , G01N33/68
摘要： The present invention relates to cell-based assays useful for screening for modulators, such as inhibitors, of activated mutant KIT tyrosine kinase receptors, which are associated with mast cell-related disorders, such as mastocytosis and various types of cancer. The invention further provides for the treatment of mast cell-related disorders with an inhibitor identified by the screening method.

7. 发明申请

WO2009076472A1 DISEASE PATHWAY-BASED METHOD TO GENEFJATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS 审中-公开
标题翻译：基于路径路径的方法，将生物标记物面板定制到特定的治疗方法
公开(公告)号：WO2009076472A1
公开(公告)日：2009-06-18
申请号：PCT/US2008/086283
申请日：2008-12-10
申请人： BLUME-JENSEN, Peter
发明人： BLUME-JENSEN, Peter
IPC分类号： G01N33/48 , G01N33/53
CPC分类号： C12Q1/6883
摘要： The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question.
摘要翻译：通过仅治疗反应性患者可以确保药物的功效增加和减少不需要的副作用。在本发明的一个实施方案中，特定药物干扰的信号传导途径与预测生物标志物和动态生物标志物一起导出，其可以在药物治疗之前和之后阅读这些途径的活性，以选择应答者患者群体。在本发明的替代实施方案中，可以鉴定药物不干扰并且已知与某种特定疾病有因果关系的某些核心途径，并且为那些能够排除这些患者的生物标志物得出患有这些药物非影响途径参与与所讨论的特定药物治疗的疾病。

8. 发明申请

WO2005057223A2 METHODS FOR IDENTIFYING MODULATORS OF ACTIVE KIT TYROSINE KINASE RECEPTOR 审中-公开
标题翻译：鉴定活性试剂盒酪氨酸激酶受体调节剂的方法
公开(公告)号：WO2005057223A2
公开(公告)日：2005-06-23
申请号：PCT/US2004/040547
申请日：2004-12-06
申请人： APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. , ANDREEV, Julian , HEALEY, Brian , BLUME-JENSEN, Peter , ARKINSTALL, Stephen, J. , DONG, Rong
发明人： ANDREEV, Julian , HEALEY, Brian , BLUME-JENSEN, Peter , ARKINSTALL, Stephen, J. , DONG, Rong
IPC分类号： G01N33/68
CPC分类号： G01N33/5011 , C07K16/2803 , C07K16/44 , C07K2317/34 , G01N33/566 , G01N33/574 , G01N2333/9121 , G01N2500/04
摘要： The present invention relates to cell-based assays useful for screening for modulators, such as inhibitors, of activated mutant KIT tyrosine kinase receptors, which are associated with mast cell-related disorders, such as mastocytosis and various types of cancer. The invention further provides for the treatment of mast cell-related disorders with an inhibitor identified by the screening method.
摘要翻译：本发明涉及用于筛选与肥大细胞相关病症（例如肥大细胞增多症和各种肥大细胞病）有关的活化的突变KIT酪氨酸激酶受体的调节剂（例如抑制剂）的基于细胞的测定法癌症类型。本发明进一步提供用筛选方法鉴定的抑制剂治疗肥大细胞相关病症。

9. 发明申请

WO2003035626A3 AZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 审中-公开
公开(公告)号：WO2003035626A3
公开(公告)日：2003-05-01
申请号：PCT/US2002/033963
申请日：2002-10-23
申请人： APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. , ARKINSTALL, Stephen, J. , ARULANANDAM, Antonio , JIANG, Xuliang , MAGAR, Sharad , NABIOULLIN, Roustem , ZHANG, John, Yingsheng , BLUME-JENSEN, Peter
发明人： ARKINSTALL, Stephen, J. , ARULANANDAM, Antonio , JIANG, Xuliang , MAGAR, Sharad , NABIOULLIN, Roustem , ZHANG, John, Yingsheng , BLUME-JENSEN, Peter
IPC分类号： C07D233/60
摘要： The invention provides substituted pyrazolidinone compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing various cancers, inflammation, septic shock, preterm labor, infertility, pain, and ischemia, and other diseases and disorders associated with MEK-1 and/or ERK-2 activation.

10. 发明申请

WO2012125411A1 METHODS OF PREDICTING PROGNOSIS IN CANCER 审中-公开
标题翻译：预防癌症预防方法
公开(公告)号：WO2012125411A1
公开(公告)日：2012-09-20
申请号：PCT/US2012/028307
申请日：2012-03-08
申请人： METAMARK GENETICS, INC. , DEVROE, Eric , WU, Chang-Jiun, Terrence , GILADI, Eldar, Yehuda , WANG, Yuxun , FRIEDLANDER, Sharon, Yehudit , BRADLEY, William, R. , SMALL, Clayton, G., III , GURVICH, Nadia , HUANG, Yi, Elaine , DAHLBERG, William, Karl , SHIPITSIN, Michail , NIFONG, Thomas, Patrick , RIMM, David, L. , CHIN, Lynda , BLUME-JENSEN, Peter
发明人： DEVROE, Eric , WU, Chang-Jiun, Terrence , GILADI, Eldar, Yehuda , WANG, Yuxun , FRIEDLANDER, Sharon, Yehudit , BRADLEY, William, R. , SMALL, Clayton, G., III , GURVICH, Nadia , HUANG, Yi, Elaine , DAHLBERG, William, Karl , SHIPITSIN, Michail , NIFONG, Thomas, Patrick , RIMM, David, L. , CHIN, Lynda , BLUME-JENSEN, Peter
IPC分类号： G01N33/50 , G01N33/574
CPC分类号： G01N33/574 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G01N33/5743 , G01N2800/50 , G01N2800/60
摘要： The present invention provides a set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use. These biomarkers, also denoted Prognosis Determinants (PDs), provide prognostic value for human cancer patients. The biomarkers can be used to supply valuable clinical information that may be useful in determining appropriate and effective methods of treatment for cancer patients.
摘要翻译：本发明提供了一组生物标志物（例如，基因和基因产物），其可以准确地通知癌症进展和复发的风险，以及它们的使用方法。这些生物标志物，也称为预后决定因子（PD），为人类癌症患者提供预后价值。生物标志物可用于提供可用于确定癌症患者的适当和有效治疗方法的有价值的临床信息。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式